Visual Performance After the Implantation of a New Trifocal Intraocular Lens
Overview
Authors
Affiliations
Purpose: To evaluate the subjective and objective visual results after the implantation of a new trifocal diffractive intraocular lens.
Methods: A NEW TRIFOCAL DIFFRACTIVE INTRAOCULAR LENS WAS DESIGNED COMBINING TWO SUPERIMPOSED DIFFRACTIVE PROFILES: one with +1.75 diopters (D) addition for intermediate vision and the other with +3.50 D addition for near vision. Fifty eyes of 25 patients that were operated on by one surgeon are included in this study. The uncorrected and best distance-corrected monocular and binocular, near, intermediate, and distance visual acuities, contrast sensitivity, and defocus curves were measured 6 months postoperatively. In addition to the standard clinical follow-up, a questionnaire evaluating individual satisfaction and quality of life was submitted to the patients.
Results: The mean age of patients at the time of surgery was 70 ± 10 years. The mean uncorrected and corrected monocular distance visual acuity (VA) were LogMAR 0.06 ± 0.10 and LogMAR 0.00 ± 0.08, respectively. The outcomes for the binocular uncorrected distance visual acuity were almost the same (LogMAR -0.04 ± 0.09). LogMAR -010 ± 0.15 and 0.02 ± 0.06 were measured for the binocular uncorrected intermediate and near VA, respectively. The distance-corrected visual acuity was maintained in mesopic conditions. The contrast sensitivity was similar to that obtained after implantation of a bifocal intraocular lens and did not decrease in mesopic conditions. The binocular defocus curve confirms good VA even in the intermediate distance range, with a moderate decrease of less than LogMAR 0.2 at -1.5 D, with respect to the best distance VA at 0 D defocus. Patient satisfaction was high. No discrepancy between the objective and subjective outcomes was evidenced.
Conclusion: The introduction of a third focus in diffractive multifocal intraocular lenses improves the intermediate vision with minimal visual discomfort for the patient.
The effects of premium intraocular lenses on presbyopia treatments.
Zhu Y, Zhong Y, Fu Y Adv Ophthalmol Pract Res. 2023; 2(1):100042.
PMID: 37846220 PMC: 10577869. DOI: 10.1016/j.aopr.2022.100042.
Yim C, Dave A, Strawn A, Chan J, Zhou I, Zhu D Ophthalmol Ther. 2023; 12(3):1757-1773.
PMID: 37052874 PMC: 10164213. DOI: 10.1007/s40123-023-00708-x.
La Cruz D, Bartlett J, Gutierrez M, Ng S Cochrane Database Syst Rev. 2023; 1:CD012648.
PMID: 36705482 PMC: 9881452. DOI: 10.1002/14651858.CD012648.pub3.
Poyales F, Perez R, Lopez-Brea I, Zhou Y, Garzon N J Ophthalmol. 2021; 2021:3514577.
PMID: 34961831 PMC: 8710168. DOI: 10.1155/2021/3514577.
Liu Y, Lan Q, Sun T, Tang C, Yang T, Duan H Graefes Arch Clin Exp Ophthalmol. 2021; 260(4):1205-1213.
PMID: 34825956 DOI: 10.1007/s00417-021-05496-3.